Acutus Medical, Inc. (“Acutus”) (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded
Gainers
Trevena (NASDAQ:TRVN) shares moved upwards by 13.3% to $0.23 during Friday's after-market session. The market value of their outstanding shares is at $38.0 million. As per the news, the Q1 earnings report came out 2 days ago.
Acutus Medical (NASDAQ: AFIB) completed patient enrollment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trial.
The trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter.